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Received March 21, 2011; accepted August 11, 2011AbstractBackground: Ewing sarcoma is extremely rare in people from East and Southeast Asia.
Methods: The records of 12 patients diagnosed with primary Ewing sarcoma and treated at our institution from 1997 to 2009 were retro-
spectively reviewed.
Results: There were seven male and five female patients and their mean age at diagnosis was 22 years (range, 12e48 years). Two patients
(16.7%) had distant metastasis at diagnosis. The primary tumor sites were the trunk in seven patients (58.3%) and the extremities in five patients
(41.7%). Eleven patients received neoadjuvant chemotherapy followed by wide excision surgery, and then adjuvant chemotherapy. One patient
received only chemotherapy without surgical intervention due to poor cardiac and pulmonary function. At a mean follow-up of 33 months,
the 2-year overall survival rate (OS) was 45.5%. Distant metastasis was the only statistically significant prognostic factor of OS in our study. The
2-year OS rates of patients with lung metastasis and without lung metastasis were 0% and 42.9%, respectively ( p ¼ 0.021). The
t(11;22)(q24:q12) translocation was present in all patients in our series.
Conclusion: We confirmed that distant metastases is highly predictive of a poor outcome, and that the t(11;22)(q24:q12) translocation was
present in all patients in our series.
Copyright  2011 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Ewing sarcoma is a highly malignant, small round-cell
tumor arising from bone or in soft tissue, and is a common
malignancy of bone in patients younger than 30 years of age.
The incidence varies among different racial groups, and is
much lower in black populations and in Eastern and South-
eastern Asians.1 The current treatment of Ewing sarcoma is* Corresponding author. Dr. Wei-Ming Chen, Department of Orthopedics
and Traumatology, Taipei Veterans General Hospital, 201, Section 2, Shih-Pai
Road, Taipei 112, Taiwan, ROC.
E-mail address: chenwm5@gmail.com (W.-M. Chen).
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doi:10.1016/j.jcma.2011.10.013neoadjuvant chemotherapy, followed by wide excision surgery,
and then adjuvant chemotherapy. The long-term survival rate
is reported to range from 60e75%. We conducted a retro-
spective study to assess the clinical outcomes and to identify
the prognostic factors of Ewing sarcoma at our institution for
greater understanding of the condition and therapeutic deci-
sions making.
2. Methods
The records of 12 patients diagnosed with primary Ewing
sarcoma and treated at our institution from 1997 to 2009 werehinese Medical Association. All rights reserved.
Table 1
Demographic data for patients with Ewing sarcoma.
Case no. Age (y) Sex Lesion site Greatest tumor
dimension (cm)
Type of surgery Current status
(2009/05)
1 42 Female Femur 11 Hip disarticulation DOD
2 29 Female Femur 5 Wide excision with APC reconstruction CDF
3 30 Female Scapula 15 Total scapulectomy DOD
4 16 Male Pelvis 5 Wide excision DOD
5 17 Male Scapula 4 Wide excision CDF
6 12 Male Pelvis 13 Wide resection with hip arthrodesis DOD
7 19 Male Clavicle 8 Wide excision DOD
8 48 Male Extra-skeletal, inguinal mass Nil Nil DOD
9 15 Male Humerus 7 Wide excision with APC reconstruction CDF
10 22 Female Tibia 9 Wide excision with autograft reconstruction CDF
11 22 Female Pelvis 12 Wide excision with hip arthrodesis CDF
12 20 Male Scapula 9 Wide excision CDF
APC ¼ allograft/recycled autograft prosthesis reconstruction; CDF ¼ continuously disease-free; DOD ¼ died of disease; Nil ¼ No pathology measurement due to
no surgical intervention.
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was obtained for the study. There were seven male and five
female patients and the mean age at diagnosis was 22 years
(range, 12e48 years). Two patients (16.7%) had distant
metastasis at diagnosis. The primary tumor sites were the
trunk in seven patients (58.3%) and the extremities in five
patients (41.7%) (Table 1). All of the patients were diagnosed
by pathological examination. EWS gene translocation was
determined by fluorescence in situ hybridization using LSI
EWSR1 Dual Color Breakapart Probe (Cat# 32-190059,
Abbott Park, Illinois, USA).
Eleven patients received neoadjuvant chemotherapy fol-
lowed by wide excision surgery, and then adjuvant chemo-
therapy. One patient received only chemotherapy withoutFig. 1. A 15-year-old boy (case 9) with Ewing sarcoma of the right proximal
reconstruction. (A) Plain radiograph showing a heterogeneous lesion with cortex
resonance imaging revealed an osteodestructive lesion with soft tissue invasion of
excision surgery with allograft-prosthesis composite reconstruction.surgical intervention due to poor cardiac and pulmonary
function. The main chemotherapy regimen consisted of
vincristine, actinomycin, cyclophosphamide, doxorubicin,
ifosfamide, and etoposide. Of five patients who required
reconstruction after wide excision surgery, two received hip
arthrodesis, one reconstruction was performed with an extra-
corporeal irradiated autograft prosthesis composite, one with
an allograft prosthesis composite (Fig. 1), and one with
a liquid nitrogen-processed autograft (Fig. 2).
The response to chemotherapy was evaluated by tumor
necrosis, graded according to the modified criteria of Rosen
et al. 2 In brief, 100% tumor necrosis is classed as grade 3;
<10% viable tumor is grade 2; from 10% to 50% viable tumor
is grade 1; and from 50% to 100% viable tumor is grade 0.humerus received wide excision surgery with allograft-prosthesis composite
disruption and periosteal reaction of the right upper humerus; (B) magnetic
the right upper humerus; (C) plain radiograph of the right humerus after wide
Fig. 2. A 23-year-old woman (Case 10) with Ewing sarcoma of the left tibia received wide excision surgery with recycled autograft reconstruction. (A) Plain
radiograph showing an osteolytic lesion with cortex invasion of the left tibia; (B) magnetic resonance imaging revealed an osteolytic lesion of the left proximal
tibia; (C) plain radiograph of the left tibia after wide excision surgery and recycled autograft reconstruction.
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Fig. 3. Kaplan-Meier analysis for overall survival rate with and without
metastasis.
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tumor size and site, local recurrence, and distant metastasis. A
survival analysis was conducted by the Kaplan-Meier method.
A p-value <0.05 was considered significant. The cut-off point
of a patient’s age and tumor volume were calculated by
a receiver operating characteristic curve. The study was
approved by the Institutional Review Board of our hospital;
the requirement for informed consent was waived because of
the retrospective nature of the study.
3. Results
The median of the follow-up survival time was 33 months
(range, 9e84 months). Of the twelve patients, six (50%) died of
the disease, and the remaining six patients were disease-free at
the time of the last follow-up. The 2-year and 3-year overall
survival (OS) rates were 45.5% and 22.7%, respectively. The 2-
year OS of the patients without metastasis was 100%, while that
of patients with metastasis was only 16.7% ( p¼ 0.014) (Fig. 3).
In addition to the two patients with distant metastases at
diagnosis, four patients (40.0%) developed distant metastases
within a mean follow-up period of 19 months. Of the six
patients with distant metastases, three had metastases to the
lungs, two to the vertebral bodies, and one patient had
metastases to both locations. Interestingly, the 2-year OS rates
of the patients with lung metastasis and those without lung
metastasis were 0% and 42.9%, respectively ( p ¼ 0.021). The
2-year OS rates of patients with and without distant bone
metastases were not significantly different ( p ¼ 0.103).
The results of the univariate analyses of clinical variables
and OS are presented in Table 2. Sex, age ( 22 years),
primary tumor site (trunk/limb; pelvis/extra-pelvic), tumorsize (>8 cm), treatment-related variables, or necrosis rate
(>90%) did not significantly influence OS. The only factor
that was significantly associated with OS was the presence of
distant metastases. In addition, metastasis to the lungs was
a more significant predictive of poor outcome as compared
with metastasis to distant bones.
4. Discussion
Ewing sarcoma is relatively rare in black populations and
in Eastern and Southeastern Asians.1 While many articles
discuss the genetic predispositions, prognostic factors, treat-
ments, and clinical outcomes in Western populations, there are
Fig. 4. Ewing sarcoma: fluorescence in situ hybridization-positive case with
EWS gene break apart. Instead of the normal fused red and green signals
(sometimes become yellow), arrows point to the separated EWS gene signal.
Table 2
Univariate analysis of factors associated with overall survival (n ¼ 12).
Variable No.
patients
2-y overall
survival (%)
p
Sex
Male 7 44.3 0.608
Female 5 53.3
Tumor size (cm)
8 8 44.4 0.301
<8 4 53.3
Age at diagnosis (y)
22 6 53.3 0.855
<22 6 44.4
Histological response to chemotherapy
Grade 3e2 (necrosis  90%) 4 31.3 0.487
Grade 1e0 (necrosis  90%) 8 0
Primary tumor site
Trunk 7 41.7 0.777
Extremities 5 60.0
Primary tumor site
Pelvic 3 46.9 0.852
Extra-pelvic 9 50.0
Disease extension
Localized 6 100 0.014
Metastatic 6 16.7
Disease extension (lung metastasis)
Lung metastasis 4 0 0.021
Non-lung metastasis 8 42.9
Disease extension (bone metastasis)
Bone metastasis 3 0 0.103
Non-bone metastasis 9 25
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because of the extreme rarity of the disease.
In our study, we found that the 2-year OS of patients with
Ewing sarcoma was 45.5%, which is quite dismal compared
with that reported in other major series.3e6 However, in our
cohort, two patients (16.7.0%) had metastases at diagnosis,
and seven patients (58.3%) had the trunk as their primary
tumor sites. The statistical power of our analyses, however, is
severely limited by the small population.
Several prognostic factors of Ewing sarcoma have been
confirmed in large series. 3,6e8 However, in our study, the only
statistically significant factor which influenced survival was
the presence of a distant metastasis ( p ¼ 0.014). Other factors
were not associated with survival in our series. It has previ-
ously been reported that patients with metastases limited to the
lungs seem to have better OS than those with metastases to
other sites. 9e11 However, our data did not support the same
conclusion; we found that the presence of lung metastasis was
more significantly predictive of poor OS as compared with
metastasis to other sites ( p ¼ 0.021).
It has been shown that up to 85% of patients with Ewing
sarcoma have the chromosomal translocation t(11;22)(q24:q12).
12 The t(11;22)(q24:q12) translocation was present in all 12
patients in our study (Fig. 4).
Due to the low incidence of Ewing sarcoma in Asian
populations, and the small population of Taiwan, Ewingsarcoma is quite rare in our country. Because of the small
number of cases in this report, the statistical power is limited.
Nevertheless, we confirmed that distant metastases are highly
predictive of a poor outcome, and found that the
t(11;22)(q24:q12) translocation was present in all of our
patients. We believe that study of innovative gene therapies,
targeted therapies, and immunotherapies can improve the
survival rate of patients with Ewing sarcoma.References
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